10x Genomics Valuation

Is TXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TXG ($36.89) is trading above our estimate of fair value ($10.97)

Significantly Below Fair Value: TXG is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TXG?

Other financial metrics that can be useful for relative valuation.

TXG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.6x
Enterprise Value/EBITDA-25.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TXG's PS Ratio compare to its peers?

The above table shows the PS ratio for TXG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.6x
SYNH Syneos Health
0.8x1.4%US$4.5b
AZTA Azenta
5.2x7.2%US$3.3b
FTRE Fortrea Holdings
1.2x2.6%US$3.6b
SHC Sotera Health
3.2x6.0%US$3.4b
TXG 10x Genomics
7.1x11.7%US$4.4b

Price-To-Sales vs Peers: TXG is expensive based on its Price-To-Sales Ratio (7.1x) compared to the peer average (3.2x).


Price to Earnings Ratio vs Industry

How does TXG's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: TXG is expensive based on its Price-To-Sales Ratio (7.1x) compared to the US Life Sciences industry average (3.8x).


Price to Sales Ratio vs Fair Ratio

What is TXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TXG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ratio6.4x

Price-To-Sales vs Fair Ratio: TXG is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TXG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$36.89
US$57.79
+56.6%
15.7%US$70.00US$30.00n/a14
Mar ’25US$45.56
US$57.79
+26.8%
15.7%US$70.00US$30.00n/a14
Feb ’25US$43.58
US$58.86
+35.1%
18.2%US$70.00US$30.00n/a14
Jan ’25US$55.96
US$56.50
+1.0%
18.4%US$70.00US$30.00n/a14
Dec ’24US$45.75
US$54.83
+19.9%
22.8%US$70.00US$30.00n/a12
Nov ’24US$34.32
US$60.33
+75.8%
21.0%US$75.00US$30.00n/a12
Oct ’24US$41.25
US$61.17
+48.3%
21.2%US$75.00US$30.00n/a12
Sep ’24US$54.05
US$62.75
+16.1%
19.6%US$75.00US$30.00n/a12
Aug ’24US$62.25
US$59.92
-3.7%
19.6%US$68.00US$30.00n/a12
Jul ’24US$55.84
US$58.50
+4.8%
21.6%US$68.00US$25.00n/a12
Jun ’24US$53.20
US$58.50
+10.0%
21.6%US$68.00US$25.00n/a12
May ’24US$52.41
US$54.55
+4.1%
23.3%US$65.00US$25.00n/a11
Apr ’24US$55.79
US$53.73
-3.7%
23.4%US$65.00US$25.00n/a11
Mar ’24US$46.63
US$52.60
+12.8%
24.0%US$65.00US$25.00US$45.5610
Feb ’24US$47.59
US$49.67
+4.4%
26.8%US$65.00US$25.00US$43.589
Jan ’24US$36.44
US$49.67
+36.3%
26.8%US$65.00US$25.00US$55.969
Dec ’23US$39.57
US$49.63
+25.4%
28.4%US$65.00US$25.00US$45.758
Nov ’23US$28.22
US$51.86
+83.8%
32.5%US$70.00US$25.00US$34.327
Oct ’23US$28.48
US$55.63
+95.3%
23.1%US$70.00US$35.00US$41.258
Sep ’23US$32.26
US$55.63
+72.4%
23.1%US$70.00US$35.00US$54.058
Aug ’23US$39.84
US$76.25
+91.4%
37.3%US$115.00US$35.00US$62.258
Jul ’23US$46.86
US$95.00
+102.7%
12.3%US$115.00US$80.00US$55.847
Jun ’23US$46.14
US$95.00
+105.9%
12.3%US$115.00US$80.00US$53.207
May ’23US$47.76
US$119.43
+150.1%
18.1%US$150.00US$85.00US$52.417
Apr ’23US$81.12
US$125.71
+55.0%
16.4%US$150.00US$95.00US$55.797
Mar ’23US$80.91
US$125.71
+55.4%
16.4%US$150.00US$95.00US$46.637

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.